These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Impact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99mTc-nitrido complexes.
    Author: Kim YS, He Z, Hsieh WY, Liu S.
    Journal: Bioconjug Chem; 2007; 18(3):929-36. PubMed ID: 17352455.
    Abstract:
    This report describes synthesis and evaluation of novel cationic 99mTc-nitrido complexes, [99mTcN(L)(PNP)](+) (L = ma, ema, tma, etma and mpo; PNP = PNP5, PNP6, and L6), as potential radiotracers for heart imaging. Cationic complexes [99mTcN(L)(PNP)](+) were prepared in two steps. For example, reaction of succinic dihydrazide with 99mTcO4(-) in the presence of excess stannous chloride and PDTA resulted in the [99mTcN(PDTA)n] intermediate, which then reacted Hmpo and PNP6 at 100 degrees C for 10-15 min to give [99mTcN(mpo)(PNP6)](+) in >90% yield. It was found that bidentate chelators have a significant impact on lipophilicity, solution stability, biodistribution, and metabolic stability of cationic 99mTc-nitrido complexes. The fact that [99mTcN(ema)(PNP6)](+) decomposes rapidly in the presence of cysteine (1 mg/mL) while [99mTcN(etma)(PNP6)](+) and [99mTcN(mpo)(PNP6)](+) remain stable for >6 h under the same conditions strongly suggests that thione-S donors in bidentate chelators increase the solution stability of their cationic 99mTc-nitrido complexes. Biodistribution studies were performed on four cationic 99mTc-nitrido complexes in Sprague-Dawley rats. [99mTcN(etma)(PNP5)](+) is of particular interest due to its high initial heart uptake (1.81 +/- 0.35 %ID/g at 5 min postinjection), and long myocardial retention (1.99 +/- 0.47 %ID/g at 120 min postinjection). The heart/liver ratio of [99mTcN(etma)(PNP5)](+) (6.06 +/- 1.48) at 30 min postinjection is almost identical that of 99mTcN-DBODC5 (6.01 +/- 1.45), and is >2 times better than that of 99mTc-sestamibi (2.90 +/- 0.22). Results from metabolism studies show that [99mTcN(etma)(PNP5)](+) has no significant metabolism in the urine, but it does show significant metabolism in feces samples at 120 min postinjection. Planar imaging studies suggest that [99mTcN(etma)(PNP5)](+) might be able to give clinically useful images of the heart as early as 30 min postinjection. [99mTcN(etma)(PNP5)](+) is a very promising candidate for more preclinical evaluations in various animal models.
    [Abstract] [Full Text] [Related] [New Search]